Dr. John Cush RheumNow
5 years 8 months ago
In the UK, NICE has recommending ed (to NHS) that filgotinib (Jyseleca) be approved for use in moderate to severe active rheumatoid arthritis (RA).https://t.co/g5zLwIa3MK
k dao KDAO2011
5 years 8 months ago
Don’t hold Benlysta for the COVID19 vaccine!
Previous studies have shown that SLE pts on Benlysta (belimumab) still have good antibody response to vaccinations (including Prevnar14, PPSV23, flu and tetanus vaccines).
@RheumNow https://t.co/4rFdcIKjkT
Dr. John Cush RheumNow
5 years 8 months ago
Canadian lupus cohort of 560 SLE pts without myositis at baseline. Over time, only 5 pts developed myositis (after mean 8.5 yrs). Incidence = 1.05 per 1000 PYs. Arthritis, Raynauds, -Sm Abs were common, but only non-Whites had increased risk of myositis. https://t.co/fzWhUADjMz
NEJM has published the interim analysis of the REGN-COV2 trial, wherein an antibody cocktail reduced viral loads with less clinical consequences.
JAMA has published the BLAZE-1 study, showing significant SARS-CoV-2 viral load reduction at day 11 and less COVID-19 progression when combination anti-spike monoclonal antibody therapy (bamlanivimab and etesevimab) was given to mild to moderate, non-hospitalized COVID-19 patients.
Dr. John Cush RheumNow
5 years 8 months ago
NEW QD Clinic
Differential Dx Myalgias & Arthralgias
https://t.co/ozawoe6RMO
Dr. John Cush RheumNow
5 years 8 months ago
Denosumab inhibiting osteolysis? 22 pts undergoing revision THR surgery for osteolysis, 10 Rx w/ denosumab had 83% fewer osteoclasts @ osteolysis membrane–bone interface. Proof concept: DEN may have osteoclast effects at implant interface https://t.co/dJ06rk0SR3
Dr. John Cush RheumNow
5 years 8 months ago
Ehlers-Danlos Syndrome pts have higher association with GI conditions (IBS, etc OR =3.57), POTS & Autonomic dysfunction (OR=4.4), food allergy (OR= 3.9), CV complications (OR 6.1; MV dx, aortic aneurysm), longer hospitalizations (OR= 1.76) https://t.co/noobvrx0cQ
Dr. John Cush RheumNow
5 years 8 months ago
Though provoking piece by Dr. Len Calabrese in Healio,He references Drs. Schett and Scher writing in Nature Reviews Rheumatology on KOLs. Both articles are about reflection on what we do, how we do it, what motivates us. Good Reads https://t.co/HDlFRVJq1a https://t.co/CtqqiZuxwo
Dr. John Cush RheumNow
5 years 8 months ago
Swedish Armed Forces study suggests the least fit are at greatest risk for developing psoriasis later inlife. From 1968 -2005 1,886,542 military recruits were followed mean 31 yrs. Low CV fitness showed higher rate of psoriasis (HR 1.35) and PsA (HR 1.44) https://t.co/52zTjMM24y
Dr. John Cush RheumNow
5 years 8 months ago
Factors Predictive of SLE Flare After HCQ Taper/Discontinuation
The benefits of hydroxychloroquine in lupus are many, but what if you were to withdraw HCQ?
Read more: https://t.co/r5iDXBEuQP https://t.co/LImqA9y8Dn
Dr. John Cush RheumNow
5 years 8 months ago
Epidemiologic study of #SLE from CDC & lupus registries estimates there are 204,295 SLE pts in USA (2018). Prevalence=72.8 SLE/100,000 and is 9 X higher in females than males (129 vs 14.6/100,000), especially among Ame Indians/Alaska Natives, Black females https://t.co/5yHVQ9UqZ4
Dr. Janet Woodcock DrWoodcockFDA
5 years 8 months ago
My note to the FDA staff: https://t.co/n2Pr2Kzrre
Dr Philip Robinson philipcrobinson
5 years 8 months ago
Toci led to poorer outcomes in this study. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ https://t.co/95zaq2CEUU
Dr. John Cush RheumNow
5 years 8 months ago
UTSW Rheum Grand Rounds - IgG4 Dz - Plasmablasts may be a useful biomarker; but is not generally available in clinical labs (must be done on fresh whole blood) @UTSWIMchief https://t.co/GlEKw0KD3O
